Last reviewed · How we verify
NCT00026689
Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols
trial in Prostate in 903 participants. Completed in 25 February 2019.
Quick facts
| Lead sponsor | National Cancer Institute (NCI) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 903 |
| Start date | 11 September 2000 |
| Estimated completion | 25 February 2019 |
| Sites | 1 location across United States |
Conditions studied
- Prostate — all drugs for Prostate →
- Brain — all drugs for Brain →
- Breast — all drugs for Breast →
- Lung — all drugs for Lung →
Sponsor
National Cancer Institute (NCI)
Who can join
Under 90, any sex, with Prostate or Brain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: -This protocol will provide a means for screening potential candidates for NCI Radiation Oncology Branch (ROB) protocols. Objectives: -To permit evaluation of patients referred to the NCI Radiation Oncology Branch in order to identify individuals who will be suitable candidates for Radiation Oncology Branch clinical research protocols. Eligibility: -Patients suspected of having, or with biopsy proven malignant disease or patients with a benign condition for whom radiotherapy is a potential treatment. Design: -This is a screening protocol. No investigational treatments will be administered on this protocol.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00026689
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate
Currently open trials in the same condition.
- NCT07220720 — POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions · Phase 2 · recruiting
- NCT07327424 — Feasibility of Suprapubic Transvesical Endoscopic Prostatectomy · NA · active not recruiting
- NCT07020364 — Feasibility and Safety of a Single Working Element for Bipolar and Laser Enucleation in Prostate Surgery: A Prospective · recruiting
- NCT03047135 — Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated · Phase 2 · active not recruiting
- NCT00923221 — Collection of Blood From Patients With Prostate Cancer · recruiting
Other National Cancer Institute (NCI) trials
Trials by the same sponsor.
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
- NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
- NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00026689 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
- Last refreshed: 12 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00026689.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing